CRISPR Therapeutics AG

Last price update: 10 Dec 24 23:00 GMT

Price:
$48.68
Open:
$49.95
Previous close:
$49.84
Day's range:
$48.34 - $50.50
Year's range:
$43.42 - $91.10
Net Income per Share:
-2.79
Price-to-Earnings ratio:
-17.45
52-week Price Range:
$48.64
Volume:
$1,657,614.00
Average volume:
$1,440,023.00

Company profile for CRISPR Therapeutics AG

CRISPR Therapeutics AG logo

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Stock exchanges:
NASDAQ
Sector:
Healthcare
Industries:
Biotechnology
Ticker:
CRSP
CIK:
0001674416
ISIN:
CH0334081137
Website:
https://www.crisprtx.com
Phone:
41 41 561 32 77
Origin:
Switzerland
Employees:
473

CRISPR Therapeutics AG News

Strength Seen in CRISPR Therapeutics AG (CRSP): Can Its 7.2% Jump Turn into More Strength?

Strength Seen in CRISPR Therapeutics AG (CRSP): Can Its 7.2% Jump Turn into More Strength?

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now?

Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now?

InvestorPlace

Two investing influencers have expressed opposite takes on how investors should play the current market. Michael Burry, of The Big Short fame, is no stranger to issuing ominous warnings for investors.

7 CRISPR Stocks With the Best Long-Term Potential

7 CRISPR Stocks With the Best Long-Term Potential

InvestorPlace

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.

3 Gene Editing Stocks to Buy Now OR You'll Be Kicking Yourself Later

3 Gene Editing Stocks to Buy Now OR You'll Be Kicking Yourself Later

InvestorPlace

To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive.

7 Biotech Stocks That Will Make You Rich in 10 Years

7 Biotech Stocks That Will Make You Rich in 10 Years

InvestorPlace

If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.

CRISPR Therapeutics AG Press Releases

Crispr therapeutics to participate in b. riley securities' 3 rd annual oncology conference

Zug, switzerland and cambridge, mass., jan. 11, 2023 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in b. riley securities' 3 rd annual oncology conference on wednesday, january 18, 2023, at 10 30 a. m. et.

Crispr therapeutics announces the appointment of alex harding, m. d., m. b. a., as head of business development

Zug, switzerland and boston, dec. 19, 2022 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today announced the appointment of alex harding, m. d., m. b. a., as senior vice president and head of business development, effective january 5, 2023. dr. harding brings extensive leadership experience in biopharma business development and corporate strategy and joins crispr therapeutics to lead the company' s business development operations.

Crispr therapeutics presents data at the society for immunotherapy of cancer ( sitc) 37 th annual meeting

Zug, switzerland and boston, nov. 10, 2022 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today presented data for ctx130 for the treatment of relapsed or refractory renal cell carcinoma ( rcc) as an oral presentation delivered by city of hope' s sumanta pal, m. d. additionally, together with collaborators at the moffitt cancer center, the company presented preclinical data in a poster presentation demonstrating the potential of potency enhanced anti cd83 car t cells in preventing relapse in acute myeloid leukemia ( aml).

Crispr therapeutics announces poster presentation on ctx110 at the american society of hematology ( ash) 2022 annual meeting

Zug, switzerland and boston, nov. 03, 2022 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today announced that it will present a poster on ctx110 , its wholly owned allogeneic car t cell investigational therapy targeting cd19 b cell malignancies, at the american society of hematology ( ash) 2022 annual meeting, taking place DEC ember 10 13, 2022, virtually and at the ernest n. morial convention center in new orleans, louisiana.

Crispr therapeutics provides business update and reports third quarter 2022 financial results

Exagamglogene autotemcel ( exa cel), formerly known as ctx001 submission to the u. s. food and drug administration ( fda) for rolling review expected to begin in november, with completion of the u. s. submission package expected in q1 2023; ema and mhra submissions are on track for q4 2022

Crispr therapeutics announces planned transition of chief operating officer

Zug, switzerland and boston, oct. 27, 2022 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today announced that its chief operating officer, lawrence klein, ph. d., will be stepping down from the company to pursue external opportunities. it is expected that he will remain with the company through year end to help ensure a smooth transition. a search is underway to find a successor to dr. klein.

Crispr therapeutics announces fda regenerative medicine advanced therapy ( rmat) DES ignation granted to ctx130 for the treatment of cutaneous t cell lymphomas ( ctcl)

Zug, switzerland and boston, sept. 28, 2022 ( globe newswire) crispr therapeutics ( nasdaq crsp), a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases, today announced that the u. s. food and drug administration ( fda) granted regenerative medicine advanced therapy ( rmat) DES ignation to ctx130 , the company' s wholly owned allogeneic car t cell therapy targeting cd70, for the treatment of mycosis fungoides and sézary SYN drome ( mf ss).

Vertex and crispr therapeutics announce global exa cel regulatory submissions for sickle cell disease and beta thalassemia in 2022

Boston & zug, switzerland ( business wire) vertex pharmaceuticals incorporated ( nasdaq vrtx) and crispr therapeutics ( nasdaq crsp) today announced that vertex has concluded discussions with the u. s. food and drug administration ( fda), and the fda granted exagamglogene autotemcel ( exa cel) a rolling review for the potential treatment of sickle cell disease ( scd) and transfusion dependent beta thalassemia ( tdt). vertex will submit its biologics licensing application ( bla) for exa cel for rolli

Crispr therapeutics provides business update and reports second quarter 2022 financial results

CLI mb 111 and CLI mb 121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel ( exa cel), formerly known as ctx001 , with the european medicines agency ( ema) and the medicines and healthcare products regulatory agency ( mhra); discussions with the u. s. food and drug administration ( fda) ongoing